MCL is a B cell malignancy with unique biological, pathological and clinical features, comprising 3鈥�10% of all non鈥怘odgkin lymphomas (NHLs) (Swerdlow听别迟听补濒,听). It was recognised as a specific entity in the revised European鈥怉merican classification of lymphoid neoplasms (REAL) classification (Harris听别迟听补濒,听) and is characterized by the chromosomal translocation t(11;14)(q13路3;q32路33), which results in overexpression of the cell cycle protein cyclin D1 (Akiyama听别迟听补濒,听; Campo听别迟听补濒,听).
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.